BIT225 will not become part of an HCV regimen. In early 2015 the new direct acting antiviral regimens will become available in Australia and these will consist of a protease and polymerase inhibitor (GS7977) - latest results coming out show that this combination gives a 100% SVR in G1 with insignificant side effects. My guess is that Biotron will abandon its HCV trials in the not too distant future to concentrate on HIV.
forget hcv, concentrate on hiv
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.002(5.00%) |
Mkt cap ! $36.09M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 4.0¢ | 3.8¢ | $4.589K | 120.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 269232 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 176124 | 2 |
View Market Depth
| Last trade - 10.53am 05/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |